MD price target increase

What happened: On May 8, Mizuho lifted its price target on Pediatrix Medical Group (MD) to $24 from $21, maintaining a Neutral rating. This followed the company's Q1 results. Separately, on April 15, JPMorgan initiated coverage of ResMed (RMD) with an "Overweight" rating and a A$37.60 price target. Truist also increased its price target on MD to $23 from $21 on April 13, reiterating a Hold rating.

Market impact: The upgrades reflect analyst optimism in the healthcare sector, particularly in small-cap stocks like MD, and companies with strong growth prospects like RMD. The price target increases suggest analysts see potential upside in these stocks, which could drive investment in the sector.

What to watch next: Investors should closely monitor MD's next earnings release, scheduled for August 5, to see if the company maintains its positive momentum. Additionally, watch for any further analyst upgrades or downgrades that could influence investor sentiment towards MD and RMD. Lastly, keep an eye on broader healthcare sector trends, as they may impact these stocks' performance.